TURKU, FINLAND: Faron Pharmaceuticals Oy, the clinical stage biopharmaceutical company, announced plans to initiate a new state of the art process for the manufacturing of interferon (IFN) beta-1a. To support this, Faron has received a €2.1 million low interest rate loan from Business Finland, the governmental innovation financing agency of Finland. The loan funds will…